Filtered By:
Infectious Disease: Endemics
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 382 results found since Jan 2013.
Microbiological profile in chronic granulomatous disease patients in a single Brazilian primary immunodeficiency center
CONCLUSION: Staphylococcus sp., Staphylococcus aureus, and Aspergillus sp. were the most frequent agents found in this cohort. M. tuberculosis should be considered in endemic area. Detection of infectious agents drives to the adequate treatment and benefits the evolution of patients with CGD.PMID:33641311 | DOI:10.15586/aei.v49i2.82
Source: Allergologia et Immunopathologia - February 28, 2021 Category: Allergy & Immunology Authors: Aim ée Filippini Bifulco Oliveira Antonio Carlos Pastorino Mayra de Barros Dorna Ana Paula Beltran Moschione Castro Jos é Roberto Mendes Pegler Beni Morgenstern Magda Maria Sales Carneiro-Sampaio Source Type: research
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses
CONCLUSIONS Our data confirm, for what we believe is the first time, the existence of unique memory CD4+ T cell clonotypes crossrecognizing SARS-CoV-2 and CCCs. The lower avidity of crossreactive TCRs for SARS-CoV-2 may be the result of antigenic imprinting, such that preexisting CCC-specific memory T cells have reduced expansive capacity upon SARS-CoV-2 infection. Further studies are needed to determine how these crossreactive T cell responses affect clinical outcomes in COVID-19 patients.FUNDING NIH funding (U54CA260492, P30CA006973, P41EB028239, R01AI153349, R01AI145435-A1, R21AI149760, and U19A1088791) was provided by ...
Source: Journal of Clinical Investigation - May 18, 2021 Category: Biomedical Science Authors: Arbor G. Dykema, Boyang Zhang, Bezawit A. Woldemeskel, Caroline C. Garliss, Laurene S. Cheung, Dilshad Choudhury, Jiajia Zhang, Luis Aparicio, Sadhana Bom, Rufiaat Rashid, Justina X. Caushi, Emily Han-Chung Hsiue, Katherine Cascino, Elizabeth A. Thompson, Source Type: research
The U.S. Government Placed a Big Bet on an Antiviral Pill to Fight COVID-19
We’re not going to vaccinate our way completely out of this pandemic. With epidemiologists around the world increasingly accepting the reality that SARS-CoV-2 and its variants will become endemic viruses—like the seasonal flu—the push is on to develop antiviral medications that can be taken at home to prevent infections from leading to hospitalization and death. Today, the Department of Health and Human Services announced that the Biden Administration has authorized $3.2 billion to accelerate the development of antivirals already in the R&D pipeline, with the hope that at least one will be ready for r...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
